SAFETY ANALYSIS OF LONG-TERM ROMIPLOSTIM USE IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

被引：0
|
作者：
Rodeghiero, F. [1 ]
Provan, D. [2 ]
Cines, D. [3 ]
Stasi, R. [4 ]
Tarantino, M. [5 ]
Nie, K. [6 ]
Jun, S. [6 ]
机构：
[1] Dept Cell Therapy & Hematol, Vicenza, Italy
[2] Royal London Hosp, Ctr Haematol, London E1 1BB, England
[3] Dept Pathol & Lab Med, Philadelphia, PA USA
[4] St George Hosp, Dept Haematol, London, England
[5] Univ Illinois, Coll Med, Peoria, IL 61656 USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0184
引用
收藏
页码：73 / 74
页数：2
相关论文
共 50 条
  • [21] Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study
    Bussel, James B.
    Kuter, David J.
    Newland, Adrian
    de Wolf, Joost T. M.
    Wasser, Jeffrey
    Chang, Paul
    Nie, Kun
    Berger, Dietmar
    BLOOD, 2009, 114 (22) : 285 - 285
  • [22] Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)
    Rodeghiero, Francesco
    Provan, Andrew
    Steurer, Michael
    Godeau, Bertrand
    Carpenter, Nancy
    Kreuzbauer, Georg
    BLOOD, 2014, 124 (21)
  • [23] ROMIPLOSTIM: EFFICACY AND SAFETY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP). SINGLE CENTRE EXPERIENCE
    Zotova, I.
    Abdulkadyrov, K.
    HAEMATOLOGICA, 2014, 99 : 208 - 208
  • [24] Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia
    Broome, Catherine M.
    Roth, Alexander
    Kuter, David J.
    Scully, Marie
    Smith, Roy
    Wang, Jennifer
    Jiang, Xiaoyu
    Reuter, Caroline
    Daak, Ahmed
    Hobbs, William
    BLOOD, 2020, 136
  • [25] Romiplostim in children with chronic immune thrombocytopenia (ITP): the French Experience
    Pasquet, Marlene
    Aladjidi, Nathalie
    Guiton, Corinne
    Courcoux, Mary-France
    Munzer, Martine
    Auvrignon, Anne
    Lutz, Patrick
    Ducassou, Stephane
    LeRoy, Gwennaelle
    Munzer, Caroline
    Leverger, Guy
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (02) : 266 - 271
  • [26] LONG-TERM USE OF THE THROMBOPOETIN RECEPTOR AGONIST ROMIPLOSTIM IN CHILDREN WITH CHRONIC/REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP) IN AN OPEN-LABEL EXTENSION STUDY (OLE)
    Bussel, James
    Buchanan, George
    Gnarra, David
    Ho, Richard
    Nie, Kun
    Eisen, Melissa
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S34 - S34
  • [27] EVALUATION OF EFFICACY AND SAFETY OF LONG-TERM ROMIPLOSTIM TREATMENT FOR PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) ENROLLED IN AN OPEN-LABEL EXTENSION STUDY: A PATIENT COHORT-ANALYSIS
    Kuter, J.
    Newland, A.
    Bussel, J.
    Wasser, J.
    Nie, K.
    Jun, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 76 - 76
  • [28] Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP)
    Lee, Eun-Ju
    Izak, Marina
    Bussel, James B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) : 379 - 382
  • [29] A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia (ITP)
    Grainger, John
    Bussel, James
    Cooper, Nichola
    Tarantino, Michael
    Blanchette, Victor
    Despotovic, Jenny
    Maschan, Alexey
    Carpenter, Nancy
    Eisen, Melissa
    Mehta, Bhakti
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S10 - S10
  • [30] Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
    Tarantino, Michael
    Bussel, James B.
    Blanchette, Victor S.
    Beam, Donald
    Roy, John
    Despotovic, Jenny M.
    Raj, Ashok
    Carpenter, Nancy
    Mehta, Bhakti
    Eisen, Melissa
    BLOOD, 2017, 130
12345